Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant

BACKGROUND: Resistance to temozolomide (TMZ) greatly limits chemotherapeutic effectiveness in glioblastoma (GBM). Here we analysed the ability of the Inhibitor-of-apoptosis-protein (IAP) antagonist birinapant to enhance treatment responses to TMZ in both commercially available and patient-derived GB...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Zakaria, Z, Tivnan, A, Flanagan, L, Murray, D W, Salvucci, M, Stringer, B W, Day, B W, Boyd, A W, Kögel, D, Rehm, M, O'Brien, D F, Byrne, A T, Prehn, J H M
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4815807/
https://ncbi.nlm.nih.gov/pubmed/26657652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.420
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados